About Us
Programs
Resources
Find a Provider
- COPE Educational Programs
Shop
Donate
- Privacy Policy
- Donor Bill of Rights

secondary to age-related macular degeneration

Alkeus Pharmaceuticals announces results from the SAGA study of oral gildeuretinol in patients with GA

mda2staff | September 23, 2024

September 19, 2024 By David Hutton Oral gildeuretinol demonstrated a clinically meaningful reduction in the geographic atrophy lesion growth rate at 24 months, supporting additional clinical development. SAGA topline data has…

Newsletter Sign-up

Name**
Email**
CAPTCHA
Comments
This field is for validation purposes and should be left unchanged.

Δ

5969 Cattleridge Boulevard, Suite 100
Sarasota, Florida 34232

(855) 962-2852 info@macularhope.org

https://www.facebook.com/macularhope/ https://twitter.com/macularhope?lang=en

The Macular Degeneration Association, Inc. is a registered 501(c)(3) non-profit corporation. A copy of the official registration and financial information may be obtained from the division of consumer services by calling toll-free within the state (1-800-help-fla) or on the consumer services website www.800helpfla.com. Registration does not imply endorsement, approval, or recommendation by the state.

| Privacy & Terms